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S U M M A R Y
Background: There are limited data on treatment-related anemia in Asian HIV-infected children.
Methods: Data from Asian HIV-infected children aged <18 years on ﬁrst-line highly active antiretroviral
therapy (HAART) were used. Children who had pre-existing severe anemia at baseline were excluded.
Anemia was graded using the United States Division of AIDS (DAIDS) 2004 table. Potential risk factors for
severe anemia were assessed by logistic regression.
Results: Data from 1648 children (51.9% female, 62.8% World Health Organization (WHO) stage 3/4) were
analyzed. Median (interquartile range) age was 6.8 (3.7–9.6) years, CD4% was 9 (3–16)%, and plasma HIV-
RNA was 5.2 (4.7–5.6) log10 copies/ml at HAART initiation in those with available testing. The most
§ This study was presented in part at the 2nd International Workshop on HIV Pediatrics, Vienna, Austria, July 16–17, 2010 (abstract O_13).
* Corresponding author. Tel.: +66 2 652 3040; fax: +66 2 252 5779.
E-mail address: torsak.b@hivnat.org (T. Bunupuradah).
1 The TREAT Asia Pediatric HIV Network: V. Saphonn* and S. Saramony, National Center for HIV/AIDS Dermatology and STDs, Phnom Penh, Cambodia; U. Vibol* and S.
Sophan, National Pediatric Hospital, Phnom Penh, Cambodia; J. Tucker, New Hope for Cambodian Children, Phnom Penh, Cambodia; F.J. Zhang, Beijing Ditan Hospital, Capital
Medical University, Beijing, China; N. Kumarasamy* and S. Saghayam, YR Gaitonde Centre for AIDS Research and Education, Chennai, India; D.K. Wati* and L.P.P. Atmikasari,
Sanglah Hospital, Udayana University, Bali, Indonesia; N. Kurniati*y and D. Muktiarti, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; S.M. Fong* and M. Thien,
Hospital Likas, Kota Kinabalu, Malaysia; N.K. Nik Yusoff* and L.C. Hai, Hospital Raja Perempuan Zainab II, Kelantan, Malaysia; K.A. Razali*, T.J. Mohamed, and N.F. Abdul
Rahman, Pediatric Institute, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia; R. Nallusamy*z and K.C. Chan, Penang Hospital, Penang, Malaysia; V. Sirisanthana*, P.
Oberdorfer, and L. Aurpibul, Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand; R. Hansudewechakul* and P. Taeprasert, Chiangrai
Prachanukroh Hospital, Chiang Rai, Thailand; P. Lumbiganon*, P. Kosalaraksa, and P. Tharnprisan, Khon Kaen University, Khon Kaen, Thailand; G. Jourdain, Program for HIV
Prevention and Treatment, Chiang Mai, Thailand; J. Ananworanich*, C. Phasomsap, and T. Suwanlerk, HIV-NAT/Thai Red Cross AIDS Research Center, Bangkok, Thailand; K.
Contents lists available at SciVerse ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j idChokephaibulkit*, W. Phongsamart, and O. Wittawatmongkol, Siriraj Hospital, Mahidol University, Bangkok, Thailand; H.K. Truong* and T.Q. Du, Children’s Hospital 1, Ho Chi
Minh City, Vietnam; C.V. Do* and M.T. Ha, Children’s Hospital 2, Ho Chi Minh City, Vietnam; K.T.K. Dung, N.V. Lam, P.N. An, and N.T. Loan, National Hospital of Pediatrics,
Hanoi, Vietnam; N.O. Le, Worldwide Orphans Foundation, Ho Chi Minh City, Vietnam; A.H. Sohn*, N. Durier, and P. Nipathakosol, TREAT Asia, amfAR – The Foundation for AIDS
Research, Bangkok, Thailand; D.A. Cooper, M.G. Law*, and A. Kariminia, The Kirby Institute, University of New South Wales, Sydney, Australia. *TApHOD Steering Committee
member; yCurrent Steering Committee Chair; zCo-Chair.
1201-9712/$36.00 – see front matter  2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.ijid.2013.04.006
T. Bunupuradah et al. / International Journal of Infectious Diseases 17 (2013) e806–e810 e807common regimens were stavudine/lamivudine/nevirapine (42%) and zidovudine/lamivudine/nevirapine
(25%). Severe anemia was identiﬁed in 47 (2.9%) children after a median time of 6 months after HAART
initiation, with an incidence rate of 5.4 per 100 child-years. Mild anemia or moderate anemia at baseline
(p = 0.024 and p = 0.005, respectively), previous or current use of zidovudine (p < 0.0001 and p = 0.013,
respectively), and male sex (p = 0.008) were associated with severe anemia. Higher weight-for-age z-
score (p = 0.004) was protective.
Conclusions: The incidence of severe anemia in Asian HIV-infected children after HAART initiation was
low and mainly occurred during the ﬁrst few months after HAART initiation. Mild to moderate anemia at
baseline and using zidovudine were independent risk factors for the development of severe anemia.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Anemia1. Introduction
Increasing access to potent antiretroviral therapy (ART) in
resource-limited settings has transformed the prognosis of HIV
infection, but adverse events may still occur after the initiation of
therapy. Anemia is commonly seen after ART initiation, whether
due to pre-existing HIV-related bone marrow suppression or as a
side effect of antiretrovirals like zidovudine (AZT).1,2 Anemia in
HIV-infected patients has been associated with a worse quality of
life, disease progression, and an increased risk of death.1,3–6
However, there is a lack of data on post-ART anemia in HIV-
infected children in Asia.1 We aimed to describe the incidence of
severe anemia after the ﬁrst 24 weeks of HAART initiation in a
regional observational cohort of Asian children, and to identify
associated factors.
2. Methods
2.1. Patients
The TREAT Asia Pediatric HIV Observational Database
(TApHOD) is a longitudinal, multicenter, cohort study of HIV-
infected children in Asia. TApHOD is a member cohort of the US
National Institutes of Health (NIH) International Epidemiology
Databases to Evaluate AIDS (IeDEA) program. Detailed information
on the overall study design and description of the cohort has been
published elsewhere.7 In brief, children eligible for inclusion in
TApHOD must be aged 18 years and have been conclusively
diagnosed with HIV by age-appropriate testing, or have a
presumptive clinical diagnosis of HIV infection deﬁned as meeting
the World Health Organization criteria for initiating HAART.8
2.2. Data collection
The study protocol was approved by the local ethics committees
or institutional review boards of each participating clinical site, the
data management and analysis center (Kirby Institute for Infection
and Immunity in Society, University of New South Wales,
Australia), and the coordinating center (TREAT Asia/amfAR,
Thailand). For this analysis, we included children from 18 clinics
in six countries: Cambodia (n = 3), India (n = 1), Indonesia (n = 2),
Malaysia (n = 4), Vietnam (n = 3), and Thailand (n = 5); these clinics
routinely provide pediatric HIV clinical care and treatment. The
database includes information on demographic characteristics and
laboratory and treatment information. This information is
collected from medical records and at clinic visits, and is entered
into computerized databases by trained staff. Data are transferred
to the Kirby Institute twice yearly for cleaning and analysis.
2.3. Eligibility criteria and deﬁnitions
The present study includes information on children (18 years)
who received HAART between November 1997 and March 2012,
and who had hemoglobin (Hb) measurements at HAART initiationand at any time during the ﬁrst 6 months of HAART. Children who
had severe anemia at baseline were excluded. We deﬁned severe
anemia in accordance with the United States NIH Division of AIDS
(DAIDS) 2004 toxicity grading table,9 as follows: Hb <10 g/dl for
children <21 days; Hb <8 g/dl for children between 22 and 35
days; Hb <7 g/dl for children between 36 and 56 days; Hb <7.5 g/
dl for children 57 days. Baseline values at HAART initiation for
laboratory and clinical measurements were deﬁned as the values
closest to HAART initiation that fell into a window of 6 months
prior to and 7 days after HAART initiation. Children were
considered lost to follow-up if the time between their last visit
and the date of the last data transfer was more than 1 year.
2.4. Statistical analysis
Baseline categorical data are presented as frequencies (%) and
continuous data as medians and interquartile ranges (IQR). The
Wilcoxon signed-rank test was used to test the differences in
medians, and the Chi-squared test or Fisher’s exact test to compare
frequencies. Follow-up started at HAART initiation and ended at
the date of diagnosis of ﬁrst severe anemia, death, or 6 months
after starting HAART. The incidence rates of severe anemia in the 6
months after HAART were calculated per 100 child-years. If anemia
occurred more than once in a single patient, the earliest event was
analyzed for both overall incidence and risk factor analyses.
Potential risk factors for the development of severe anemia were
explored by univariate and multivariate Cox proportional hazards
models. The variables and possible confounders investigated
included: age (<1.5, 1.5–4, 5–11, 12–14, and 15 years), sex,
World Health Organization (WHO) clinical stage (stage 1, 2, 3, and
4), CD4% (<10, 10–14, and 15%), HIV-RNA log10 copies/ml (<5
and 5 log10 copies/ml), anemia (mild, moderate, and no anemia),
weight, height, and exposure to AZT and nevirapine (NVP). Weight
and height measurements were converted into age- and sex-
standardized z-scores. For the height-for-age z-score (HAZ) the
WHO 2006/2007 Child Growth Standards were used.10 WHO 1977
standards were used for weight-for-age z-scores (WAZ), to allow for
scoring children >10 years of age.11 AZT and NVP use as part of a
HAART regimen were included as time-dependent variables and
categorized as: current use (currently receiving it or stopped 60
days before starting a new regimen), ever used (had used it but
stopped >60 days before starting new regimen), and never used.
Countries were categorized as upper middle-income (Thailand,
Malaysia), lower middle-income (Indonesia, India, and Vietnam),
and low-income (Cambodia).12 Variables were included in the full
model if they were associated with severe anemia in the univariate
analysis with p < 0.10. A ﬁnal model was then created by using a
forward step-wise method, and a p-value of <0.05 was considered
statistically signiﬁcant in the adjusted analysis. Analyses were done
using STATA version 11.0 (Stata Corp., College Station, TX, USA).
3. Results
By the end of March 2012, 3448 children who had been
recruited into TApHOD had received HAART when aged 18 years.
Table 1
Patient characteristics at HAART initiationa
Characteristics All
(n = 1648)
No anemia
(n = 1123)
Mild anemia
(n = 407)
Moderate anemia
(n = 118)
Age, years, median (IQR) 6.8 (3.7–9.6) 7.3 (4.5–10.0) 5.9 (2.9–8.6) 5.1 (2.1–8.0)
Female sex, n (%) 51.9 52.8 49.4 51.7
Country by income level, n (%)
Thailand/Malaysia 1087 (66.0%) 758 (67.5%) 256 (62.9%) 73 (61.9%)
Indonesia/India/Vietnam 304 (18.5%) 199 (17.7) 75 (18.4%) 30 (25.4%)
Cambodia 257 (15.6%) 166 (14.8%) 76 (18.7%) 15 (12.7%)
CD4%, median (IQR) 9 (3–16) 11 (5–17) 6 (2–13) 6 (2–11)
Missing data 123 82 34 7
CD4 count, cells/mm3, median (IQR) 228 (60–513) 273 (89–547) 115 (23–377) 122 (24–400)
Missing data 136 77 50 9
HIV-RNA (log10 copies/ml), median (IQR) 5.2 (4.7–5.6) 5.0 (4.5–5.5) 5.4 (5.0–5.8) 5.5 (5.1–5.9)
Missing data 853 553 227 73
WHO clinical staging, n (%)
Stage 1/2 612 (37.1) 495 (44.1) 152 (37.3) 26 (9.3)
Stage 3 846 (51.3) 499 (44.4) 145 (35.6) 42 (35.6)
Stage 4 190 (11.5) 129 (11.5) 110 (27.0) 50 (42.4)
Weight for age z-score, median (IQR) 2.3 (3.6 to 1.2) 1.9 (3.1 to 1.0) 3.1 (4.2 to 2.0) 3.5 (4.9 to 2.3)
Missing data 51 31 14 6
Height for age z-score, median (IQR) 2.2 (3.2 to 1.3) 2.0 (2.9 to 1.1) 2.7 (3.6 to 1.8) 3.2 (3.9 to 2.4)
Missing data 111 65 33 13
Hemoglobin (g/dl), median (IQR) 10.6 (9.6–11.6) 11.2 (10.5–12.0) 9.3 (9.0–9.6) 8.1 (7.8–8.3)
HAART, highly active antiretroviral therapy; IQR, interquartile range; WHO, World Health Organization.
a Classiﬁcation of anemia was based on the US NIH Division of AIDS 2004 toxicity grading table.9
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Figure 1. Kaplan–Meier estimates of the probability of severe anemia in 1648
children in the ﬁrst 6 months of HAART, by anemia status at baseline.
Table 2
Incidence of severe anemia in the ﬁrst 6 months of HAART by baseline anemia statusa
Anemia at
baseline
Children
(n = 1648)
Severe
anemia
Incidence per 100
child-years (95% CI)
Hb at HAART, g/dl,
median (IQR)
Hb at severe anemia,
g/dl, median (IQR)
No anemia 1123 20 3.3 (2.2–5.2) 10.9 (10.3–11.3) 6.6 (5.4–7.1)
Mild anemia 407 19 9.0 (5.7–14.0) 9.4 (9.0–9.7) 6.3 (4.5–6.9)
Moderate anemia 118 8 13.3 (6.7–26.6) 8.1 (7.7–8.3) 6.4 (5.5–7.1)
HAART, highly active antiretroviral therapy; CI, conﬁdence interval; Hb, hemoglobin; IQR, interquartile range.
a Classiﬁcation of anemia was based on the US NIH Division of AIDS 2004 toxicity grading table.9
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values reported, 616 (18%) with no Hb results in the ﬁrst 6 months
after HAART, and 85 (2.5%) who had severe anemia at baseline. The
analysis was consequently based on 1648 children (Table 1), of
whom 1123 (68.1%) had no anemia at HAART initiation, 407
(24.7%) had mild anemia, and 118 (7.2%) had moderate anemia.
About half (51.9%) of the children were girls. The median age was
6.8 (IQR 3.7–9.6) years. The median pre-HAART CD4% was 9 (IQR
3–16)%. Eleven percent of children had a history of prior mono-
and/or dual-therapy with nucleoside reverse transcriptase inhibi-
tors (NRTI). First-line non-nucleoside reverse transcriptase inhibi-
tor (NNRTI)-based HAART was used in 91.7% and protease inhibitor
(PI)-based HAART in 7.8%. The initial NNRTI-based HAART regi-
mens were stavudine (d4T)/lamivudine (3TC)/NVP in 42%, AZT/
3TC/NVP in 25%, AZT/3TC/efavirenz (EFV) in 17%, and d4T/3TC/EFV
in 13% of children. The most common ritonavir-boosted PI-based
HAART regimens were AZT/3TC/lopinavir/ritonavir (LPV/r) in 47%,
d4T/3TC/LPV/r in 40%, and others (e.g., saquinavir/3TC/LPV/r,
indinavir/3TC/LPV/r) in 14% of children.
The 1800 children who were excluded from the study had
similar median CD4 counts and CD4% to those included. However
they were younger (median age 5.4 vs. 6.8 years) and had lower
median WAZ (3.0 vs. 2.5; p < 0.0001). Excluded children were
more likely to be WHO stage 4 (21% vs. 12%; p < 0.0001) and WHO
stages 1–2 (49% vs. 37%; p < 0.0001) at baseline.
3.1. Incidence rate and predictors of severe anemia
Forty-seven (2.9%) of 1648 children had severe anemia during
the ﬁrst 6 months of HAART initiation (incidence rate 5.4 per 100
child-years, 95% conﬁdence interval (CI) 4.1–7.2). The number (%)of children who developed severe anemia during months 0–2 was
26 (55.3%), during months 2–4 was 15 (31.9%), and during months
4–6 was 6 (12.8%). The incidence was 7.4 (95% CI 5.2–10.6) per 100
child-years in boys and 3.5 (95% CI 2.2–5.8) per 100 child-years in
girls. Table 2 shows the incidence rate of severe anemia by baseline
anemia status. A Kaplan–Meier analysis to estimate the probability
of severe anemia categorized by baseline anemia status is shown in
Figure 1.
Results of the multivariate analyses showed an increased risk of
early severe anemia for children who had mild anemia or moderate
anemia at baseline (p = 0.024 and p = 0.005, respectively), previous
or current use of AZT (p < 0.0001 and p = 0.013, respectively), and
Table 3
Factors associated with the incidence of severe anemia within the ﬁrst 6 months of HAART initiation
Characteristics Events Person-years Univariate Adjusted
HR (95% CI) p-Value HR (95% CI) p-Value
Age, yearsa
<1.5 8 81 2.33 (0.94–5.78) 0.069 1.10 (0.40–3.07) 0.852
1.5–4.9 17 212 1.89 (0.89–4.03) 1.00 1.56 (0.71–3.40) 0.264
5–11.9 11 320 0.81 (0.35–1.87) 0.626 0.78 (0.34–1.80) 0.559
12 11 259 1.0
Sex
Female 16 454 1.0 - 1.0
Male 31 418 2.10 (1.15–3.84) 0.016 2.36 (1.25–4.48) 0.008
CD4%a
0–9% 33 403 2.50 (1.15–5.40) 0.02 1.89 (0.79–4.48) 0.153
10–14% 3 160 0.58 (0.15–2.17) 0.415 0.68 (0.17–2.64) 0.576
15% 8 245 1.0 1.0
Missing 3 64
HIV-RNA at baselinea
<5 log10 3 158 1.0
5 log10 17 264 3.36 (0.98–11.4) 0.053 2.43 (0.70–8.40) 0.160
Missing 27 450
WHO stagea
1–2 13 430 1.0 1.0
3 18 269 2.20 (1.08–4.49) 0.030 2.03 (0.94–4.39) 0.072
4 16 173 3.04 (1.46–6.31) 0.003 2.38 (1.03–5.49) 0.042
Weight-for-age z-score - 0.77 (0.69–0.87) <0.0001 0.80 (0.68–0.93) 0.004
Height-for-age z-scorea - 0.82 (0.66–1.02) 0.075 1.25 (0.90–1.73) 0.185
Anemia at HAART
No anemia 20 599 1.0 1.0
Mild 19 212 2.67 (1.43–5.00) 0.002 2.16 (1.11–4.22) 0.024
Moderate 8 60 3.98 (1.75–9.03) 0.001 3.77 (1.49–9.54) 0.005
Zidovudine use
Never used 13 498 1.0 1.0
Ever used 33 367 3.44 (1.80–6.52) <0.0001 5.30 (2.67–10.53) <0.0001
Currently used 1 7 11.90 (1.47–96.53) <0.020 14.72 (1.78–121.97) 0.013
Nevirapinea
Never used 23 320 1.0
Ever used 23 527 0.61 (0.34–1.08) 0.089 0.93 (0.50–1.71) 0.806
Currently used 1 25 0.84 (0.11–6.30) 0.867 1.27 (0.17–9.79) 0.816
HAART, highly active antiretroviral therapy; HR, hazard ratio; CI, conﬁdence interval; WHO, World Health Organization.
a These variables were only signiﬁcant in the univariate analysis. The hazard ratio was obtained by adding each to the ﬁnal model.
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was protective.
3.2. Long-term outcomes
The 407 children who had baseline mild anemia were followed
for a median (IQR) of 5.4 (2.5–6.8) years. Among these, 134 (33%)
used AZT in their initial regimen. At their last visit, the median
(IQR) Hb was 12.0 (11.1–12.8) g/dl, CD4% was 27.0 (20.0–32.0)%,
CD4 count was 737 (497–1032) cells/mm3, and of 344 with HIV-
RNA testing, 80% had HIV-RNA <400 copies/ml.
The 118 children with baseline moderate anemia were followed
for a median (IQR) of 4.7 (2.1–6.6) years, and had median (IQR) Hb
of 11.8 (10.7–12.7) g/dl, CD4% of 27.3 (18.4–31.8)%, CD4 count of
780 (468–1219) cells/mm3, and 76% of 84 tested had HIV-RNA
<400 copies/ml. Twenty-three (19%) of these children used AZT in
their initial regimen.
The 47 children who developed severe anemia during the ﬁrst 6
months of ART were followed for a median of 2.7 (IQR 1.0–5.1)
years. At their last visit, the median (IQR) Hb was 11.3 (7.2–12.7) g/
dl, CD4% was 23.5 (7.1–32.0)%, CD4 count was 509 (149–1000)
cells/mm3, and of 37 with available test results, 76% had HIV-RNA
<400 copies/ml.
4. Discussion
Anemia is a common complication in HIV-infected children and
is associated with disease progression and poor outcomes.1,13 In
our report, the incidence of severe anemia after ART initiation inchildren without severe anemia at baseline was low at 2.9%. This
may reﬂect the historically predominant use of d4T in ﬁrst-line
therapy regimens in our cohort. The incidence of post-HAART
severe anemia in our cohort was comparable to reports of HIV-
infected adults in Asia2 and Africa.14
In our study, mild to moderate pre-HAART anemia and the use
of AZT were associated with post-HAART severe anemia, and
higher WAZ was protective. Although WHO guidelines recommend
avoiding AZT in children with severe anemia,15 it may be
appropriate to extend this to children with mild or moderate
anemia during the initial phase of their treatment when other
options are available, particularly in the malnourished or severely
immunosuppressed. Age younger than 6 years, advanced HIV
disease stage, and the presence of stunting (HAZ <2) were
associated with anemia in a study of HIV-infected children in
India.13 However, we failed to identify these associations in this
cohort. In addition, Shet et al. reported no association of sex and
anemia in Indian HIV-infected children,13 but we found that boys
had more than twice the risk of severe early anemia. The reasons
for this ﬁnding are unclear. Additional studies of childhood
nutrition, use of vitamin and mineral supplements, and hemoglo-
binopathy in the cohort may help explain our results.
The limitations of this study are primarily reﬂective of the
observational nature of the data and the availability of laboratory-
based monitoring of children in our cohort on HAART. Around half
of the children in our cohort were excluded from analysis as they
were missing baseline pre-HAART Hb levels. We performed an
additional sub-group analysis for the occurrence of severe anemia
among 445 children who did not have baseline Hb levels but had
T. Bunupuradah et al. / International Journal of Infectious Diseases 17 (2013) e806–e810e810test results reported during the ﬁrst 6 months of HAART. Twenty-
two (4.9%) of these children had severe anemia, with a median Hb
level of 6.5 (5.3–6.8) g/dl. This was higher than in our analysis sub-
cohort, and their exclusion may have biased our results towards
children who were more likely to have Hb measurements, whether
due to disease progression, malnutrition, or level of clinic
resources. In addition, we did not have clinical information about
other possible causes of anemia (e.g., history of hemoglobinopathy,
iron deﬁciency anemia, concurrent bone marrow-suppressive
medications), nor additional clinical management or outcomes
data for the patients who developed severe anemia.
Kosalaraksa et al. reported that mild to moderate anemia was
common (around 50%) among 299 ART-naı¨ve Thai and Cambodian
children without advanced HIV.16 However, the prevalence of iron
deﬁciency anemia was low (2.7%) and the majority of cases were
caused by carriage of a thalassemia trait (47%) and anemia of chronic
disease (42%).16 Therefore, iron supplementation in anemic HIV-
infected Asian children without further assessment of red blood cell
indices or iron levels may not necessarily be beneﬁcial.
In conclusion, the incidence of severe anemia in Asian HIV-
infected children was low (2.9%) during their initial period of
HAART. However, mild to moderate anemia at baseline and the use
of AZT were independent risk factors for the development of severe
anemia. Monitoring of Hb during the ﬁrst few months of HIV
treatment for children with baseline mild to moderate anemia and
for children using AZT is warranted and should be implemented
more consistently in our region.
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